Document is current

Article History

Received: 23 December 2024

Accepted: 2 September 2025

First Online: 5 November 2025

Competing interests

: CKL reports grants from Roche, Amgen, AstraZeneca and Merck KGaA, honoraria from AstraZeneca, Amgen, Janssen, GSK, Boehringer Ingelheim, MSD, Roche, Gilead, Novartis and Glenmark and meeting attendance support from AstraZeneca and Janssen. KEF reports honoraria from Janssen and Gilead, and meeting attendance support from BMS, Merck/MSD, Gilead, and Pfizer. KN reports support for the present manuscript with an AACR-AstraZeneca Ovarian Cancer Research Fellowship, and support from the Stafford Fox Medical Research Foundation. MM reports a US patent, and AstraZeneca stock as an employee incentive. YCL reports institutional grants form BeiGene, honoraria from AstraZeneca and Eisai, and participation in an advisory board with AstraZeneca and GSK. JL reports honoraria from AstraZeneca, Eisai, Gilead, Novartis and GSK, meeting attendance support from GSK and Novartis, participation in an advisory board with AstraZeneca, and a leadership role as chair of the ANZGOG uterine tumor working group. SB-H reports honoraria from AstraZeneca, Gilead, GSK, Novartis, MSD and Eisai, meeting attendance support from Novartis, and reports a leadership role as a member of the ANZGOG ovarian cancer tumor working group. YA reports consulting fees from Eisai, GSK, AstraZeneca, Pfizer, MSD and Daiichi Sankyo, honoraria from GSK, AstraZeneca, MSD, Eisai and IQVIA, meeting attendance support from MSD, participation in and advisory board with GSK, Eisai, AstraZeneca, MSD and Pfizer, and a leadership role through participation on the ANZGOG Research Advisory Committee. CS reports honoraria from AstraZeneca, Gilead, GSK, Eli Lilly, Novartis, MSD and Eisai, participation in and advisory board with AstraZeneca, and a leadership role as a member of ANZGOG ovarian cancer working group. SS-N reports honoraria from AstraZeneca, MSD and Eisai, meeting attendance support from MSD and a leadership role on the South Australian Health Cancer Drug Committee. PB reported participation in an advisory board with GSK and AstraZeneca. DZ reports honoraria from Merck and Bayer. MAQ reports participation in an advisory board with GSK. ATP reports support for the current manuscript through and NHMRC investigator grant and a leadership role as past president of the Australian Bioinformatics and Computational Biology Society Inc. CV reports support for the current manuscript with support from the Stafford Fox Medical Research Foundation and from Victorian Medical Research Acceleration Fund, institutional grants from AstraZeneca, Boehringer Ingelheim, IDEAYA Biosciences and Eisai and the recipient of royalties from Venetoclax. MF reports investigator-initiated grant support for the study from AstraZeneca, consulting fees from AstraZeneca, Novartis, GSK, Incyclix, AbbVie and BioNTech, honoraria from AstraZeneca, GSK, MSD and Limbic, participation in an advisory board from AGITG IDSMB, Endo-3 trial and Domenica trial, and institutional grants from AstraZeneca, BeiGene and Novartis. CLS reports support for the current manuscript through an investigator led grant from AstraZeneca, an NHMRC investigator grant, support from the Stafford Fox Research Foundation, the OASIS philanthropic research grant from ANZGOG, and the Victorian Medical Research Acceleration Fund, research grants from AstraZeneca, Eisai, BeiGene, Sierra Oncology, Boehringer Ingelheim and IDEAYA, royalties from Navitoclax, Genentech, Abbott, and Walter and Eliza Hall Institute of Medical Research, meeting attendance support from AstraZeneca, advisory board participation with AstraZeneca, Eisai, Sierra Oncology, MSD and Takeda, a leadership role as GCIC director, chair of the board of the international rare cancer initiative, and chair of the board of ANZGOG, and drug provision as part of a research agreement from AstraZeneca, Clovis Oncology, Eisai, BeiGene, Sierra Oncology, Boehringer Ingelheim and Ideaya.MP reports support for the current manuscript through AstraZeneca clinical trial funding support, RMIT and WEHI translational research funding, and ANZGOG translational research funding, and a patent provisionally lodged on blood biomarkers to identify PARPi responders. All other authors (A.J., A.L., A.E.R.K., N.T.B., C.Da, C.De, E.C., G.G., H.A., U.G.K., J.B., K.D., K.S.A., M.C., M.J.W., R.L.O.C., and S.S.) declare no competing interests.